Mayo Clinic Comprehensive Cancer Center — Research

Below are current clinical trials.

2041 studies in Mayo Clinic Comprehensive Cancer Center — Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study of Participant Preferences for Education and Decision Making in K-ras Tumor Molecular Testing for Colorectal Cancer

   Rochester, Minn.

   The purpose of this study is to describe knowledge about and quality of physician/patient communication surround tumor testing for K-ras to inform treatment and/or prognosis or to enhance cancer management in patients w/sporadic CRC. Evaluate decision-making satisfaction and decisional conflict surrounding the use of K-ras molecular testing to enhance cancer management. Identify educational needs and preferences of patients to enhance use of molecular testing for cancer treatment decision-making.

2. A Study to Evaluate Contouring Organs at Risk for Treatment Planning

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to determine:  if the artificial intelligence (AI)-generated results are less arduous than manual tracing by radiation oncologist, and the non-inferiority of the quality of AI vs. manual tracing.  These aims will be evaluated in a clinical environment to investigate the impact of an AI algorithm on the clinical workflow. 

   Radiotherapy treatment planning requires precise calculations of radiation exposure, not only for the target volumes (tissue containing malignancy), but of nearby organs-at-risk (OARs), in which the exposure needs to be minimized. Manual segmentation of these organs is a time-consuming task with high interobserver variability. Producing these segmentations automatically will reduce the time required for treatment planning and improve the interobserver variability.

3. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery

   Rochester, Minn.

   This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after cryosurgery in combination with pembrolizumab may work better in treating patients with melanoma.

4. A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. It also aims to evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma and to evaluate the effectiveness of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. 

5. Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

   Rochester, Minn.

   The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

6. A Study to Evaluate ctDNA Diagnostics in Recurrent Breast Cancer Patients

   Rochester, Minn.

   The purpose of this study is to to establish a minimally-invasive blood based test for the detection of clinically actionable genetic changes in breast cancer patients.

7. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

   Rochester, Minn.

   Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or metastatic TNBC

   Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination

   Hypothesis: Restore (for melanoma) or enhance (for TNBC) sensitivity to checkpoint inhibitors (CPI) by appropriate and effective stimulation of the subject's innate and adaptive immune systems in those subjects who have failed 1st line therapy

   The study will incorporate Simon's optimal 2-stage design with sample size fixed at 12 subjects each in Stage 1 for advanced melanoma and for Triple Negative Breast Cancer (TNBC) subjects. The safety criterion of ≤ 4 (or ≤ 33%) subjects with Grade 3/4 adverse events in Cycle 1 within either tumor type must be met in order to proceed to Stage 2. The starting dose is 4 mg/kg for Imprime PGG. In the event there are a total of > 4 (or > 33%) of subjects with Grade 3/4 adverse events in Cycle 1, the dose of Imprime PGG will be reduced to 2 mg/kg, and Stage 1 will be repeated at a dose of 2 mg/kg with an additional cohort of n=12 subjects. For the dose that meets the safety criterion in Stage 1, at least 1 response in melanoma subjects and 2 responses in TNBC subjects amongst the 12 subjects within each tumor type must be observed in order to proceed to Stage 2.

   Stage 2 will enroll an additional 17 subjects with melanoma, and 30 subjects with TNBC. For the dose that meets the Stage 1 safety criterion, success will be declared if at least 4 amongst the total of up to 29 subjects with melanoma, and 13 amongst the total of up to 42 subjects with TNBC achieve an objective response.

8. Study Using Chromogranin A as Surveillance Biomarker in Patients with cARcinoids

   Rochester, Minn.

   The purpose of this study is to monitor and validate the performance and stability of the BRAHMS Chromogranin A (CgA) II KRYPTOR Assay in patients with Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).

9. A Study of Characteristics and Post-surgical Outcomes of Pediatric Patients Diagnosed with Lipoblastoma

   Rochester, Minn.

   The purose of this study is to examine the characteristics and post-surgical outcomes of pediatric patients diagnosed with lipoblastoma.

10. A Study to Better Understand How to Predict and Manage Patients Who are at High Risk for Developing Rheumatic Immune-related Adverse Events While Receiving Treatment for Melanoma

    Rochester, Minn.

    The purpose of this study is to:

    1. Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and,
    2. Further inform our understanding on the pathogenesis of classic rheumatologic diseases.
    3. Establish a repository of biological samples from patients with irAE and corresponding rheumatologic